Searched for
PHARMACEUTICAL MANUFACTURING REGULATIONS
Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...- WHO seeks details from India over oxytocin-linked deaths; licences of manufacturer cancelledThe World Health Organisation (WHO) has sought details from the Indian government after reports linked oxytocin injections made by Jackson ...
- Madhusudan Kela-backed fund buys stake in IPO-bound Steamhouse India for Rs 40 croreAce investor Madhusudan Kela's funds, along with Niveshaay Sambhav Fund, have injected Rs 49.99 crore into Steamhouse India via a pre-IPO p...
- India’s development ladder after AI: What comes next?India’s future prosperity may increasingly depend on empowering its smaller economic units to become more productive using AI.
- India needs innovation at scale to fulfill ambition of becoming global discovery hub: Dr Reddy'sIndia must shift from minor advancements to large-scale innovation to become a global discovery hub, according to Dr. Reddy's Laboratories ...
- For investors who focus on the long term: 5 mid-cap stocks from different sectors with upside potential up to 28%When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 24%When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- HealthQuad raises Rs 550 crore, eyes Rs 1,700 crore fundHealthQuad has secured Rs 550 crore for its third fund. The venture capital firm aims to raise Rs 1,700 crore to back early-growth companie...
- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...
- India attracted $843 billion in FDI between 2014-15 and 2025-26: OfficialIndia has seen a significant rise in Foreign Direct Investment, attracting USD 843 billion between 2014-15 and 2025-26. Key government init...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- India's biggest trade bet comes with six red flagsIndia may be adding more trade partners, but its latest FTA report card comes with several red marks. A new study by the Global Trade Resea...
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supplyUzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...
- Drug companies directed to step up vigil on adverse reactionsIndia's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...
Load More
